Cargando…
Treatment of malignancy-associated hypercalcemia with cinacalcet: a paradigm shift
Palliation of symptoms related to malignancy-associated hypercalcemia (MAH) is essential and clinically meaningful for patients, given the continued poor prognosis, with high morbidity and mortality associated with this disease process. Historically, agents have been temporizing, having no impact on...
Autores principales: | O’Callaghan, Sondra, Yau, Hanford |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Bioscientifica Ltd
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7923058/ https://www.ncbi.nlm.nih.gov/pubmed/33289687 http://dx.doi.org/10.1530/EC-20-0487 |
Ejemplares similares
-
Hypercalcemia of malignancy treated with cinacalcet
por: Asonitis, Nikolaos, et al.
Publicado: (2017) -
Hypercalcemia of Malignancy Complicated by Osteonecrosis of the Jaw Treated With Cinacalcet
por: Vasquez, Libia, et al.
Publicado: (2023) -
Utility of Cinacalcet in Familial Hypocalciuric Hypercalcemia
por: Sethi, Bipin Kumar, et al.
Publicado: (2017) -
Cinacalcet for the Treatment of Humoral Hypercalcemia of Malignancy: An Introductory Case Report with a Pathophysiologic and Therapeutic Review
por: Sheehan, Michael, et al.
Publicado: (2020) -
Amelioration of hypercalcemia by cinacalcet treatment in a subject with relapsing acquired hypocalciuric hypercalcemia: A case report
por: Sanada, Junpei, et al.
Publicado: (2021)